Treatment of congenital adrenal hyperplasia in children aged 0-3 years: a retrospective multicenter analysis of salt supplementation, glucocorticoid and mineralocorticoid medication, growth and blood pressure

Imagem de Miniatura
Arquivos
art_MARTINS_True_neurogenic_thoracic_outlet_syndrome_late_outcomes_from_2022.PDF (1.03 MB)
Citações na Scopus
6
Tipo de produção
article
Data de publicação
2022
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
BIOSCIENTIFICA LTD
Autores
NEUMANN, Uta
LINDE, Annelieke van der
KRONE, Ruth E.
KRONE, Nils P.
GUVEN, Ayla
GURAN, Tulay
ELSEDFY, Heba
POYRAZOGLU, Sukran
DARENDELILER, Feyza
Citação
EUROPEAN JOURNAL OF ENDOCRINOLOGY, v.186, n.5, p.587-596, 2022
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Objectives: International guidelines recommend additional salt supplementation during infancy in classic congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency. The influence of corticoid medication and growth has not been assessed. Aim: To investigate the current use of salt supplementation, fludrocortisone (FC) and hydrocortisone (HC) dosage as well as weight, height, BMI and blood pressure (BP) in CAH children aged 0-3 years. Methods: Retrospective multicentre analysis using data from the I-CAH registry. Salt-treated (ST) and non-salt-treated (NST) children were compared regarding FC and HC dosage, weight, height and BP at 0, 3, 6, 9, 12, 18, 24, 30, and 36 months. Results: We analysed 2483 visits of 331 patients born after year 2000 in 13 countries (male, n = 145) with 203 ST patients (61%). NST children had significantly higher FC dosages at 1.5-4.5 months and higher HC dosages until 1.5 months of age. No differences in weight, length and BP between subgroups were observed. Children of the whole cohort showed increased BMI-SDS during the study period and about half of the reported BP readings were >P95. Conclusion: In children treated with additional salt supplementation, FC and HC dosages are lower during the first months of life but without differences in weight, length and BP until 3 years of age compared to NST children. All children showed an increase in BMI-SDS and a high rate of BP readings >P95 until 3 years, indicating the start of weight gain and negative effects on blood pressure already in very early life.
Palavras-chave
URI
https://observatorio.fm.usp.br/handle/OPI/49115
Referências
  1. Al-Dahhan J., 2002, Archives of Disease in Childhood, V86, pF120, DOI 10.1136/fn.86.2.F120
  2. Ali SR, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20184405
  3. [Anonymous], WHO CHILD GROWTH STA
  4. Bonfig W, 2011, HORM RES PAEDIAT, V75, P32, DOI 10.1159/000316973
  5. Bonfig W, 2007, J CLIN ENDOCR METAB, V92, P1635, DOI 10.1210/jc.2006-2109
  6. Bonfig W, 2018, HORM RES PAEDIAT, V89, P7, DOI 10.1159/000481775
  7. Bonfig W, 2016, AM J HYPERTENS, V29, P266, DOI 10.1093/ajh/hpv087
  8. Bonfig W, 2014, CLIN ENDOCRINOL, V81, P871, DOI 10.1111/cen.12498
  9. Chen W, 2011, AM J HYPERTENS, V24, P77, DOI 10.1038/ajh.2010.176
  10. Claahsen-van der Grinten HL, 2011, PHARMACOL THERAPEUT, V132, P1, DOI 10.1016/j.pharmthera.2011.05.004
  11. Claahsen-van der Grinten HL, 2022, ENDOCR REV, V43, P91, DOI 10.1210/endrev/bnab016
  12. Concolino P, 2018, MOL DIAGN THER, V22, P261, DOI 10.1007/s40291-018-0319-y
  13. de Onis M, 2006, ACTA PAEDIATR, V95, P76, DOI 10.1080/08035320500495548
  14. de Onis M, 2010, AM J CLIN NUTR, V92, P1257, DOI 10.3945/ajcn.2010.29786
  15. Fewtrell M, 2017, J PEDIATR GASTR NUTR, V64, P119, DOI 10.1097/MPG.0000000000001454
  16. Flynn JT, 2017, PEDIATRICS, V140, DOI 10.1542/peds.2017-3035
  17. Gattineni J, 2015, PEDIATR NEPHROL, V30, P2085, DOI 10.1007/s00467-013-2666-6
  18. Geleijnse JM, 1997, HYPERTENSION, V29, P913, DOI 10.1161/01.HYP.29.4.913
  19. Gomes LG, 2013, CLINICS, V68, P147, DOI [10.6061/clinics/2013(02)OA05, 10.6061/CLINICS/2013(02)OA05]
  20. HAYCOCK GB, 1993, PEDIATR NEPHROL, V7, P871, DOI 10.1007/BF01213376
  21. He FJ, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f1325
  22. Hermanussen M, 2003, HORM RES, V59, P180, DOI 10.1159/000069321
  23. Hindmarsh PC, 2009, BEST PRACT RES CL EN, V23, P193, DOI 10.1016/j.beem.2008.10.010
  24. Kourime M, 2017, ORPHANET J RARE DIS, V12, DOI 10.1186/s13023-017-0603-7
  25. Krone N, 2015, CLIN ENDOCRINOL, V82, P478, DOI 10.1111/cen.12700
  26. Krone N, 2013, J CLIN ENDOCR METAB, V98, pE346, DOI 10.1210/jc.2012-3343
  27. Krone N, 2009, BEST PRACT RES CL EN, V23, P181, DOI 10.1016/j.beem.2008.10.014
  28. Maccabee-Ryaboy N, 2016, CLIN ENDOCRINOL, V85, P528, DOI 10.1111/cen.13086
  29. Martinerie L, 2009, PEDIATR RES, V66, P323, DOI 10.1203/PDR.0b013e3181b1bbec
  30. Mooij CF, 2015, HORM RES PAEDIAT, V83, P414, DOI 10.1159/000374112
  31. Mooij CF, 2010, HORM RES PAEDIAT, V74, P328, DOI 10.1159/000308891
  32. MULLIS PE, 1990, EUR J PEDIATR, V150, P22, DOI 10.1007/BF01959473
  33. Neumann U, 2018, CLIN ENDOCRINOL, V88, P21, DOI 10.1111/cen.13447
  34. New MI, 2013, P NATL ACAD SCI USA, V110, P2611, DOI 10.1073/pnas.1300057110
  35. Pofi R, 2020, J CLIN ENDOCR METAB, V105, P314, DOI 10.1210/clinem/dgz055
  36. Rao G, 2016, PEDIATRICS, V138, DOI 10.1542/peds.2015-3616
  37. Silva IN, 1997, ARCH DIS CHILD, V77, P214, DOI 10.1136/adc.77.3.214
  38. Simonetti L, 2018, HUM MUTAT, V39, P5, DOI 10.1002/humu.23351
  39. Speiser PW, 2018, J CLIN ENDOCR METAB, V103, P4043, DOI 10.1210/jc.2018-01865
  40. Subbarayan A, 2014, CLIN ENDOCRINOL, V80, P471, DOI 10.1111/cen.12265
  41. Wasniewska M, 2011, J ENDOCRINOL INVEST, V34, P159, DOI 10.1007/BF03347048

Coleções
Artigos e Materiais de Revistas Científicas - FM/MCM
Artigos e Materiais de Revistas Científicas - LIM/42